

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME

CONVEYING PARTY DATA

Name	Execution Date
Merrion Research II Limited	12/20/2007

RECEIVING PARTY DATA

Name:	Merrion Research III Limited
Street Address:	3rd Floor Biotechnology Building
Internal Address:	Trinity College Enterprise Centre
City:	Dublin 2
State/Country:	IRELAND

PROPERTY NUMBERS Total: 28

Property Type	Number
Application Number:	09160496
Application Number:	09163510
Application Number:	09510560
Application Number:	11400689
Application Number:	11450641
Application Number:	09743173
Application Number:	10145194
Application Number:	10145180
Application Number:	60302540
Application Number:	10482081
Application Number:	09386266
Application Number:	11463194
Application Number:	09386709
Application Number:	08746411
Application Number:	10329130

CH \$1120.00 09160496

Application Number:	09573252
Application Number:	09443986
Application Number:	09671089
Application Number:	10764235
Application Number:	10185815
Application Number:	11147083
Application Number:	10116275
Application Number:	60491157
Application Number:	10909267
Application Number:	10566458
Application Number:	11572838
Application Number:	11761233
Application Number:	11733007

CORRESPONDENCE DATA

Fax Number: (919)854-1401
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 919-854-1400
Email: brosser@myersbigel.com
Correspondent Name: Betty-Lou Rosser
Address Line 1: 4140 Parklake Avenue
Address Line 2: Suite 600
Address Line 4: Raleigh, NORTH CAROLINA 27612

ATTORNEY DOCKET NUMBER:	9701-1
NAME OF SUBMITTER:	Betty-Lou Rosser

Total Attachments: 10
source=97011Assn2#page1.tif
source=97011Assn2#page2.tif
source=97011Assn2#page3.tif
source=97011Assn2#page4.tif
source=97011Assn2#page5.tif
source=97011Assn2#page6.tif
source=97011Assn2#page7.tif
source=97011Assn2#page8.tif
source=97011Assn2#page9.tif
source=97011Assn2#page10.tif

PATENT ASSIGNMENT

THIS Assignment is effective as of the 20th day December 2007, by and between **Merrion Research II Limited**, company registration number 385197 (formerly known as **Adaptiv Research II Limited**) a company incorporated under the laws of Ireland, having a place of business at 3rd Floor Biotechnology Building, Trinity College Enterprise Centre, Dublin 2, Ireland (hereafter "Assignor") and **Merrion Research III Limited**, company registration number 442413 a company incorporated under the laws of Ireland, having a place of business at 3rd Floor Biotechnology Building, Trinity College Enterprise Centre, Dublin 2, Ireland (hereafter "Assignee").

WHEREAS, Assignor is the owner of the patents and patent applications set forth in the attached Schedule A (the "Patent Rights").

WHEREAS Assignor has agreed to assign the Patent Rights to Assignee.

WHEREAS Assignee is desirous of acquiring the entire and exclusive rights, title and interest in, to and under the Patent Rights.

NOW, THEREFORE, In consideration of the issuance of one (1) Ordinary Share of Merrion Research III Limited by Assignee to Assignor receipt of which Assignor hereby acknowledges, the receipt and sufficiency of which are hereby acknowledged, Assignor, intending to be legally bound, does hereby sell, assign and transfer to Assignee and Assignee's successors and assigns, the entire right, title and interest in and to the Patent Rights as may have been vested in Assignor, including, but not limited to, the right to claim priority under statute, regulation, Treaty of the Paris Convention, and in all letters patent, including all continuations, divisions, continuations-in-part, reissues, extensions or re-examinations thereof, throughout the world, together with all claims for damages by reason of any past, present or future infringement or other unauthorised use of the said Patent Rights for Assignee's own use and enjoyment, and for the use and enjoyment of Assignee's successors, assigns or other legal representatives, to the end of the term for

which the Patent Rights are in effect, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made.

Assignor authorises and requests competent authorities in all countries to record Assignee as owner of the Patent Rights, including any continuations, divisions, continuations-in-part, reissues, extensions or re-examinations thereof, and to issue any and all letters patent thereon to Assignee, as owner of the entire right, title and interest in, to and under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.

Further, Assignor hereby agrees to sign all lawful papers, execute all divisional, continuation, renewal, re-examination and reissue applications, and to execute all necessary assignment papers to cause any and all of said Patent Rights to be issued to said Assignee, and to make all rightful oaths and generally do everything reasonably possible to aid said Assignee and its representatives to obtain proper protection for the said Patent Rights in any and all countries.

It is hereby certified by or on behalf of Assignor that the property transferred herein qualifies in its entirety as intellectual property as defined by Section 101(1) Stamp Duties Consolidation Act, 1999 and as such, the aforementioned transfer of intellectual property is exempted from the charge to Stamp Duty under the provisions of Section 101(2) Stamp Duties Consolidation Act, 1999.

Assignor further agrees that the terms, covenants and conditions of this Assignment shall inure to the benefit of Assignee, its successors and assigns, and legal representatives, and shall be binding on Assignor, its legal representatives and assigns.

This Assignment shall be governed by and interpreted in accordance with the laws of Ireland and the parties hereby submit to the exclusive jurisdiction of the Irish courts.

This Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS of which Assignor and Assignee have caused this Assignment to be signed and executed by the undersigned duly authorised officers.

MERRION RESEARCH II LIMITED

Company Number 385197

BY: *[Signature]*

NAME: Jonathan O'Connell


TITLE Secretary

Before me personally appeared the above-named individual, to me known to be the person who is described in and who executed the foregoing Assignment and who acknowledged to me that he executed the same of his own free will for the purpose therein expressed.

[Signature]


Notary Public
18-04-08

(SEAL)



MERRION RESEARCH III LIMITED

Company Number 442413


BY: 


NAME: Joun Leena

TITLE Director

Before me personally appeared the above-named individual, to me known to be the person who is described in and who executed the foregoing Assignment and who acknowledged to me that he executed the same of his own free will for the purpose therein expressed.

(SEAL)


Notary Public
18-04-08



SCHEDULE A

Title	Status	Patent/ Publication/ Application Numbers
Composition and method for enhancing paracellular transport across cell layers (antisense occludin)	Canada Japan Europe Great Britain South Africa United States Ireland PCT	2,304,313 2000-512941 1 017 801 1 017 801 9808624 6,346,613 1 017 801 WO 99/015649 – PCT/IE98/00080
Composition and method for enhancing transport across gastrointestinal tract cell layers (babassu oil)	Ireland United States	83587 6,423,334
Solid oral dosage form containing an enhancer (C8-C10)	Canada Europe Japan United States United States United States	2,363,123 2000 0 905 186.3 2000-600624 09/510,560 11/400,689 11/450,641
Enhanced delivery of nucleic acid based drugs	Canada Japan United States PCT Europe Ireland Switzerland United Kingdom	2,371,095 2000-616823 09/743,173 WO 00/067798 1 173 217 1 173 217 1 173 217 1 173 217

SCHEDULE A contd.

Permeation enhancers - branched chains	United States Canada Europe Japan PCT	10/145,194 2,446,619 2002 0 731 786.6 2002-588986 WO 02/092069 – PCT/US02/15210
Permeation enhancers – isostearic acid salts	Europe Japan PCT United States Canada	2002 0 731 787.4 2002-588987 WO 02/092070 10/145,180 2,446,622
Delivery of a bioactive material (liquid)	United States Canada Europe Japan PCT United States	10/482,081 2,452,056 2002 0 767 768.1 2003-510010 WO 03/003999 – PCT/IB02/03651 60/302,540

SCHEDULE A contd.

Method for inducing a cell-mediated immune response and proved parenteral vaccine formulations thereof	Canada Japan United States Europe Ireland United Kingdom United States	2,341,358 2000-567237 1/1463,194 1 107 783 1 107 783 1 107 783 7,087,236
Oral vaccine compositions	PCT Europe Canada Japan PCT United States	WO 00/012125 – PCT/IE99/00087 1999 0 940 438.7 2,341,352 2000-567236 PCT/IE99/00086 09/386709
Peptides which enhance transport across tissues and methods of identifying and using the same	Canada Japan Europe Austria Belgium Switzerland/Liechtenstein Germany Denmark Spain Finland France Great Britain Greece Ireland Italy	2,235,226 1997-518025 0 859 959 246808 0 859 959 0 859 959 69629385.4 0 859 959 ES2203722T3 0 859 959 0 859 959 0 859 959 0 859 959 0 859 959 0 859 959 0 859 959

SCHEDULE A contd.

	<p>Luxembourg Monaco Netherlands Portugal Sweden Ireland United States United States PCT United States</p>	<p>0 859 959 0 859 959 0 859 959 0 859 959 0 859 959 80466 6,117,632 6,521,737 WO 97/017613 – PCT/IE96/00072 10/329,130</p>
<p>Retoinversion peptides that target GIT transport receptors and related methods</p>	<p>Canada Japan United States Europe Belgium France Germany Ireland Italy Luxembourg Monaco Switzerland United Kingdom PCT</p>	<p>2,349,290 2000-583950 09/443,986 1 131 344 1 131 344 1 131 344 69926531.2 1 131 344 1 131 344 1 131 344 1 131 344 1 131 344 1 131 344 1 131 344 WO 00/031123 – PCT/IE99/00117</p>
<p>Membrane penetrating peptides</p>	<p>Canada Japan United States</p>	<p>2,386,231 2001-530372 10/764,235 (US Pat. 7,268,214)</p>

SCHEDULE A contd.

	United States Europe Ireland United Kingdom	6,780,846 1 230 267 1 230 267 1 230 267
	PCT	WO 01/027154 – PCT/IB00/01491
M-cell specific targeting ligands	United States Canada Europe Japan	11/147,083 2,451,741 2002 0 760 458.6 2003-510683
	United States	6,916,789
	PCT	WO 03/004517 – PCT/IB02/03401
Genetic analysis of M cells and methods and compositions targeting M cell receptors (ATLAS array)	Europe Canada	2002 0 777 590.7 2,443,644
	PCT United States	WO 03/004646 – PCT/IB02/03866 10/116,275
Process And Machine For Automated Manufacture Of Covered Retard Forms	United States	60/491,157
Gastroretentive formulator	Canada United States Japan Belgium Europe France	2,532,951 10/566,458 2006-521710 1 648 425 1 648 425 1 648 425

SCHEDULE A contd.

	Germany Ireland United Kingdom	1 648 425 1 648 425 1 648 425
	PCT United States	WO 05/009199 – PCT/US04/03414 10/909,267
Improved EGTS machine	Canada Europe Japan United States United States PCT	2,574,912 2005 0 769 781.5 2007-523031 11/572,853 (abd.) 11/572,838 WO 06/010635
Depsipeptide with enhancer	PCT United States United States	PCT/US07/13693 11/761,233 60/812,523
Solid oral dosage form containing an enhancer	PCT United States	PCT/US07/08935 11/733,007